AU2022288937A1 - Anti-upar antibodies and uses thereof - Google Patents

Anti-upar antibodies and uses thereof Download PDF

Info

Publication number
AU2022288937A1
AU2022288937A1 AU2022288937A AU2022288937A AU2022288937A1 AU 2022288937 A1 AU2022288937 A1 AU 2022288937A1 AU 2022288937 A AU2022288937 A AU 2022288937A AU 2022288937 A AU2022288937 A AU 2022288937A AU 2022288937 A1 AU2022288937 A1 AU 2022288937A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022288937A
Other languages
English (en)
Other versions
AU2022288937A9 (en
Inventor
Corina AMOR VEGAS
Scott W. Lowe
Michel Sadelain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2022288937A1 publication Critical patent/AU2022288937A1/en
Publication of AU2022288937A9 publication Critical patent/AU2022288937A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022288937A 2021-06-11 2022-06-10 Anti-upar antibodies and uses thereof Pending AU2022288937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209941P 2021-06-11 2021-06-11
US63/209,941 2021-06-11
PCT/US2022/032956 WO2022261405A1 (en) 2021-06-11 2022-06-10 Anti-upar antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2022288937A1 true AU2022288937A1 (en) 2023-12-14
AU2022288937A9 AU2022288937A9 (en) 2024-01-11

Family

ID=84425502

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022288937A Pending AU2022288937A1 (en) 2021-06-11 2022-06-10 Anti-upar antibodies and uses thereof

Country Status (7)

Country Link
US (1) US20240117066A1 (https=)
EP (1) EP4352107A4 (https=)
JP (1) JP2024521415A (https=)
CN (1) CN117693529A (https=)
AU (1) AU2022288937A1 (https=)
CA (1) CA3221895A1 (https=)
WO (1) WO2022261405A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
CN121248786A (zh) * 2025-12-08 2026-01-02 上海宏成药业有限公司 抗尿激酶纤溶酶原激活物受体抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3504963B2 (ja) * 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
WO2011100620A2 (en) * 2010-02-12 2011-08-18 The Regents Of The University Of California Upar binding agents and methods of use thereof
WO2013020898A1 (en) * 2011-08-05 2013-02-14 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
US20170021020A1 (en) * 2015-07-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibody and vaccine targeting filamentous bacteriophage
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof
AU2020214796A1 (en) * 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2020160518A1 (en) * 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker

Also Published As

Publication number Publication date
CN117693529A (zh) 2024-03-12
CA3221895A1 (en) 2022-12-15
JP2024521415A (ja) 2024-05-31
US20240117066A1 (en) 2024-04-11
EP4352107A1 (en) 2024-04-17
WO2022261405A1 (en) 2022-12-15
AU2022288937A9 (en) 2024-01-11
EP4352107A4 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
US11725059B2 (en) Antibodies targeting B-cell maturation antigen and methods of use
US20210388081A1 (en) Antibodies targeting fc receptor-like 5 and methods of use
TWI564306B (zh) 雙特異性抗體
KR102553752B1 (ko) 인터페론 알파 및 오메가 항체 길항제
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN102549017A (zh) 抗-EpCAM抗体
WO2022242758A1 (zh) 抗cd73抗体及其应用
US20240117066A1 (en) Anti-upar antibodies and uses thereof
JP2017529331A (ja) Ｃｘｃｒ３に結合する抗原結合タンパク質
KR102356187B1 (ko) 항-gm-csf 항체 및 이것의 사용
US20240254253A1 (en) ANTI-uPAR ANTIBODIES AND USES THEREOF
US10647766B2 (en) Anti-CXCL12 antibody molecules and their uses
JP7688150B2 (ja) 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
HK40120943A (zh) Ccr8抗原结合单元及其用途
CN121449745A (zh) 靶向baff-r的全人源抗体
HK40002168B (en) Antibodies targeting fc receptor-like 5 and methods of use
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
HK1253584B (zh) 与cd38结合的抗体治疗剂

Legal Events

Date Code Title Description
SREP Specification republished